Study Summary
This trial is testing the safety of a new drug, talquetamab, given in different combinations. They hope to find a safe dose of the drug to use in future.
- Multiple Myeloma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
4 Primary · 11 Secondary · Reporting Duration: Up to 1 year and 10 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
5 Treatment Groups
Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide
1 of 5
Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib
1 of 5
Treatment Regimen C: Talquetamab + Lenalidomide
1 of 5
Treatment Regimen E: Talquetamab + Pomalidomide
1 of 5
Treatment Regimen A: Talquetamab + Carfilzomib
1 of 5
Experimental Treatment
182 Total Participants · 5 Treatment Groups
Primary Treatment: Talquetamab · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 0 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |
Frequently Asked Questions
How many participants are the maximum allowable for this research experiment?
"Affirmative. According to clinicaltrials.gov, this research venture is presently recruiting patients; it was initially submitted on September 22nd 2021 and has been updated as recently as November 3rd 2022. The protocol requires the recruitment of 176 volunteers at 12 distinct sites." - Anonymous Online Contributor
What sort of results is this research looking to achieve?
"According to the research sponsor, Janssen Research & Development, LLC, the primary outcome assessed over a Up to 1 year and 6 months time frame will be Number of Participants with Dose Limiting Toxicity (DLT). This trial is also set to monitor secondary outcomes such as Very Good Partial Response (VGPR) or Better Response Rate which measures whether participants achieved a VGPR or better response according to established criteria; Complete Response (CR) or Better Response Rate measuring CR or higher responses based on IMWG 2016 guidelines; and finally, assessing for anti-drug antibodies among patients being treated with daratumumab." - Anonymous Online Contributor
What is the principal application of Talquetamab?
"The most common use for Talquetamab is to treat patients that have experienced two prior systemic chemotherapy regimens. This medication can also be employed in the management of amyloidosis, refractory multiple myeloma and cell transplants." - Anonymous Online Contributor
Have any other investigations been conducted utilizing Talquetamab?
"At the moment, there are 444 clinical trials researching Talquetamab with 78 in Phase 3. Although most of these studies occur near Chicago, Illinois, a total of 18450 sites facilitate research on this medication." - Anonymous Online Contributor
What is the prevalence of this research program in North American medical facilities?
"This clinical trial is being conducted in a total of 12 different places, with locations such as Birmingham, San Francisco and Hackensack. To reduce the amount of travel required for participation, it is ideal to pick the closest medical centre possible." - Anonymous Online Contributor
Are there any openings for participants in this trial?
"Correct. Clinicaltrials.gov displays that this clinical research, first published on September 22nd 2021 is actively recruiting participants. 176 individuals from 12 trial sites need to be included in the study." - Anonymous Online Contributor
Are there known risks associated with Talquetamab utilization?
"Given the limited amount of safety and efficacy data, Talquetamab was rated a 1 on our team's scale from one to three." - Anonymous Online Contributor